As of November 6, 2026, Acurx Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: ACXP). The largest insider holding is David P. Luci, the chief executive and president, with 1,147,541 shares (21.8% of shares outstanding), per Form 4 of January 8, 2025. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13G, August 14, 2025).
Is this your company?
About to sign with, pay or invest in Acurx Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Acurx Pharmaceuticals, Inc. a real, registered company?
- Acurx Pharmaceuticals, Inc. files with the SEC under CIK 1736243 (its SEC filings).
- Its shares are listed under the ticker ACXP on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Staten Island, New York, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Acurx Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital (filed 2025-08-14).
Who are Acurx Pharmaceuticals, Inc.'s owners and officers?
Acurx Pharmaceuticals, Inc.: incorporated in Delaware; business address in Staten Island, New York; industry Pharmaceutical Preparations (S-1, 2026-09-08).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-04-29)
- : Executive Officer, Director (Form D, 2026-04-29)
- : Executive Officer (Form D, 2026-04-29)
- : Director (Form D, 2026-04-29)
- : Director (Form D, 2026-04-29)
- : Director (Form D, 2026-04-29)
- : Director (Form D, 2026-04-29)
- : Director (Form D, 2026-04-29)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2025-11-14 | Armistice Capital, LLC | 4.99% |
| Schedule 13G, 2025-08-14 | Armistice Capital, LLC | 8.7% |
Want the whole picture on Acurx Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Acurx Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Acurx Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Acurx Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 1,147,541 shares (21.8% of shares outstanding), 1,097,458 held directly and 50,083 indirectly (Form 4, 2025-01-08).
- , a director and 10% owner: 1,014,043 shares (19.2% of shares outstanding), 1,010,196 held directly and 3,847 indirectly (Form 4, 2025-01-08).
- , a director: 142,183 shares (2.7% of shares outstanding), 137,183 held directly and 5,000 indirectly (Form 4, 2025-01-08).
- , a director: 27,708 shares (0.53% of shares outstanding) (Form 4, 2025-01-08).
- , a director: 27,546 shares (0.52% of shares outstanding), 21,776 held directly and 5,770 indirectly (Form 4, 2025-01-08).
Shares outstanding: 5,269,921 as of 2026-08-13, from the company's latest SEC cover page.
How much has Acurx Pharmaceuticals, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-04-29 | $4.59M | $4.59M |
| Form D, 2025-06-27 | $3.98M | $3.98M |
| Form D, 2025-05-20 | $0 | $12M |
| Form D, 2025-03-21 | $3.38M | $3.38M |
| Form D, 2025-01-17 | $2.40M | $2.40M |
Latest IPO step: Acurx Pharmaceuticals, Inc. filed to go public (S-1, 2026-09-08).
IPO filings: S-1, 2026-09-08, S-1, 2026-05-04, S-1, 2026-05-04, S-1, 2026-02-02, S-1, 2025-10-20; ticker ACXP on Nasdaq Capital Market.
Keep reading
More on Acurx Pharmaceuticals, Inc. and the records around it.
Acurx Pharmaceuticals, Inc. elsewhere on the record
- Company profile and every filing Apr 2026
- Form D filing Apr 2026
- Form D filing Jun 2025
Companies that share a holder
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Related pages
Funding and filing history5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/acurx-pharmaceuticals-inc